Could an organ rejection drug help fight brain cancer?
NCT ID NCT05236036
First seen Jan 15, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This early-phase trial tests whether adding mycophenolate mofetil (a drug usually used to prevent organ rejection) to standard chemotherapy and radiation can help treat glioblastoma, an aggressive brain cancer. The study involves 60 newly diagnosed or recurrent glioblastoma patients and aims to find the safest dose and check for side effects. It is not a cure, but a step toward improving existing treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Northwestern Lake Forest Hospital
Lake Forest, Illinois, 60045, United States
-
Northwestern Medicine Warrenville
Warrenville, Illinois, 60555, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.